Search This Blog

Tuesday, October 8, 2019

Amag Pharma down on petition to remove Makena from U.S. market

AMAG Pharmaceuticals (AMAG -3.5%) is under modest pressure on below-average volume in apparent reaction to a petition filed with the FDA by the consumer advocacy group Public Citizen requesting the removal of Makena (hydroxyprogesterone caproate injection) from the U.S. market. The agency first approved the drug, under accelerated review status, in February 2011 to reduce the risk of preterm birth in at-risk pregnant women.
Public Citizen says that the drug’s effectiveness is unproven, citing the results from a 2018 Phase 3 study, PROLONG, that failed to show a statistically significant treatment benefit compared to placebo.
https://seekingalpha.com/news/3504556-amag-pharma-4-percent-petition-remove-makena-u-s-market

Polio-Like AFM in Kids: Is a Virus to Blame?

Acute flaccid myelitis (AFM) appears to have a viral etiology, but exactly which virus is causing the polio-like illness remains unknown, according to an analysis of pediatric cases reported to the CDC from 2015 to 2017.
Among 193 children with confirmed AFM, 79% reported a respiratory or febrile illness from 2 to 7 days before limb weakness set in, and the cases tended to cluster in the late summer or fall, reported Tracy Ayers, PhD, of the CDC in Atlanta, Georgia, and colleagues.
Although no single pathogen was identified as the driving force behind these cases, viral pathogens were found in almost half of patients (47%), with coxsackievirus A16 detected in the cerebrospinal fluid and serum of one patient and enterovirus D68 — the most predominant pathogen detected in the 2014 outbreak — detected in serum of another, they wrote in Pediatrics.
Together, these findings “strongly suggest a viral etiology, including [enteroviruses],” the authors stated.
AFM, a rare condition characterized by acute onset of focal limb weakness and spinal cord gray matter lesions, was classified as such during the 2014 outbreak, in which 120 individuals contracted the disorder from August through December of that year.
AFM made national news in 2018, with a total of 228 confirmed cases in 41 U.S. states, and four confirmed cases in 2019. The spike in reported cases in 2018 was so dramatic that the CDC announced they would start tracking AFM cases.
Importantly, 143 cases (74%) in this study occurred in 2016, “fitting within the larger epidemiological context of a biennial pattern of AFM outbreaks in the U.S. documented from 2014 to 2018,” wrote Samuel Dominguez, MD, PhD, of Children’s Hospital Colorado in Aurora, and colleagues, in an accompanying commentary.
However, myelitis in the grey matter of the spinal cord has been associated with poliovirus, non-polio enteroviruses, flaviviruses, and autoantibody conditions, Dominguez and colleagues noted.
“As such, a single etiology to explain all cases of the clinical syndrome of AFM at all times would not be expected,” they wrote.
Although enterovirus D68 appears to be the most likely driving force behind AFM, widespread enterovirus circulation makes it difficult to establish a causal relationship when collected from nonsterile sites, the authors reported.
“Serologic evidence of widespread infection with EV-D68, even before the first notable increase of AFM in 2014, suggests that if EV-D68 was the primary cause of AFM in 2014 and 2016, other factors must play a role in the development of this rare outcome,” they wrote.
AFM outbreaks need to be analyzed separately from the “background noise” of endemic AFM, Dominguez’s group wrote. Developing intrathecal enterovirus antibody tests for cerebrospinal fluid could also improve the ability to diagnose cases, they added.
All cases in this analysis were confirmed to be AFM by an expert panel of pediatricians and neurologists. The CDC requested sterile site and nonsterile-site specimens from each of the patients with confirmed AFM, which were tested for poliovirus, enteroviruses, rhinoviruses, and parechoviruses.
Overall, 305 incidents were reported from 43 states, of which 193 pediatric cases were confirmed. Children tended to be white (53%) and male (61%) with a median age of 6 years.
Across the 3-year study period, the majority of cases occurred from August through November (61%). In 2016 when the number of cases peaked, 88% of cases occurred from August through November, the authors reported.
At the time of limb weakness onset, one-third of patients had cranial nerve findings (33%), quadriplegia (36%), or required mechanical ventilation (33%), the authors reported. Over one-quarter presented with an altered mental status at this time (28%).
Poliovirus was not detected in any cases, and enterovirus D68 was found in about one-quarter of confirmed cases from 2015 through 2017 (24%), although it was also found in patients with misclassified AFM.
In CDC laboratories, 32 of 90 children with upper respiratory specimens were positive for enterovirus and rhinovirus (36%) and 15 of 77 kids with stool samples were positive for enterovirus and rhinovirus (19%), the authors reported.
Also, in non-CDC laboratories, 61 of 151 children who had respiratory specimens tested were positive for enterovirus and rhinovirus (46%) and 22 of 78 patients with stool samples were positive for enterovirus and rhinovirus (52%), they added.
The number of cases to be reported in the study period across the U.S. could be underestimated as AFM is not a nationally notifiable condition, and has a range of clinical severity, the authors reported. Also, enterovirus surveillance is limited by geographic variability and an inability to determine type-specific trends by year, they added.
“Enhanced AFM surveillance with focused analysis of distinct signals from outbreak periods is essential to targeting the development of specific therapeutics and preventive vaccines to combat this potentially devastating neurologic condition,” according to Dominguez and colleagues.
Ayers and co-authors disclosed no relevant relationships with industry.
Dominguez disclosed no relevant relationships with industry. A co-author disclosed support from the National Institute of Allergy and Infectious Diseases.

Red meat study sees major pushback

A recent guideline published in the Annals of Internal Medicine is getting some serious blowback from medical professionals. That’s because the guideline stated adults can continue eating red and processed meat without much harm to their health, arguing that previous research showing health harms from these products is weak.
The guideline went against decades of research pointing to negative health impacts from consumption of red and processed meat, including higher risks of cancer, heart disease and other ailments.
Now, some medical experts are slamming the guideline after many headlines claimed the study puts red meat back on the table for many Americans. One Harvard University professor, Walter Willett, called out the researchers for “ignorance” by not utilizing “major parts of the available evidence,” he told Market Watch. Other groups, including the American College of Cardiology, have spoken out about the study, stating it was “alarmed” by the “reckless” findings.
And there is another major problem with the study published in Annals: the researcher leading the study, Bradley Johnston, PhD, an epidemiologist at Dalhousie University in Canada, did not disclose he actually had ties to the meat industry. The study had more than a dozen researchers on its publication, and Johnstone was among those who declared no conflicts of interest. However, Johnstone has a history of these types of studies looking to discredit health guidelines––paid for by industry trade groups with interests in the matter, The New York Times reported.
Specifically, Johnstone was the author of a study that looked to undermine evidence that advised people to eat less sugar. An industry trade group supported by major companies like McDonald’s, Coca-Cola and Pepsi, International Life Sciences Institute, paid for that study, which was published in December 2016. A major beef processor, Cargill, was also a member of ILSI, and the group has been accused by the World Health Organization of trying to undermine public health interests, the NY Times reported.
The money for the sugar study was given in 2015, allowing Johnstone to report no conflicts of interest within the past three years for the most recent red meat guideline. ISLI is not listed as funding the recent red meat study.
Johnstone has also backtracked slightly on his previous sugar study, saying he was “naïve” to work on the sugar guidelines, the NY Times reported. Editors at the Annals of Internal Medicine have also defended their decision to publish the red and processed meat study.
https://www.healthexec.com/topics/leadership/red-meat-study-sees-major-pushback

Cracks in Purdue’s proposed opioid settlement as Arizona backs out

The U.S. state of Arizona withdrew its support for a proposed nationwide opioid settlement with Purdue Pharma LP, saying the maker of OxyContin sought to “undermine material terms of the deal,” according to a court filing on Monday.

Since Purdue filed for bankruptcy protection in September, Arizona is the first state to switch sides in the looming showdown over the privately-held company’s proposed settlement, which it has estimated is worth more than $10 billion.
Purdue reached the deal last month with 24 states and the local governments that have filed the bulk of the more than 2,600 lawsuits against the company.
The lawsuits allege Purdue and its Sackler family owners contributed to a public health crisis by aggressively marketing opioids while downplaying their overdose risks, which contributed to nearly 400,000 deaths since 1999, according to U.S. statistics.
Last week, court filings from states and local governments opposing the settlement asserted that Purdue steered up to $13 billion in profits to the Sackler family, more than triple the amount previously cited in litigation.
A lawyer for some of the Sacklers last week said in a statement that much of the money was paid in taxes and reinvested in businesses that will be sold as part of the proposed settlement.
Arizona’s filing offers little explanation of why the state backed away from its initial support. “At nearly every turn during the course of subsequent negotiations, debtors have sought to undermine material terms of the deal,” it said.
Arizona’s attorney general did not immediately respond to a request for comment. Purdue declined to comment.
U.S. Bankruptcy Judge Robert Drain in White Plains, New York, will consider on Friday Purdue’s request for an injunction to pause the litigation for about nine months. Purdue said it needs time to try to settle the remaining cases.
Purdue also asked Drain to shield the Sacklers from litigation, even though they have not filed for bankruptcy, partly because the family has proposed contributing at least $3 billion towards the settlement.
Opponents of the settlement accused the family of using Purdue’s bankruptcy to shield their wealth from victims.
With Arizona, 25 states now oppose the deal. Kentucky and Oklahoma reached prior settlements with Purdue.
In addition to pursuing a case in state court against Purdue, Arizona is also pursuing a novel lawsuit that it filed directly with the U.S. Supreme Court, saying the unusual move was justified by the national importance of the opioid crisis.

https://www.marketscreener.com/news/Cracks-in-Purdue-s-proposed-opioid-settlement-as-Arizona-backs-out–29351001/

Merck taps 4D pharma for bacterial vaccine R&D project

Merck has teamed up with 4D pharma to develop bacterial strains as vaccines. The deal gives Merck the chance to pick up three candidates against undisclosed indications in return for an upfront fee and up to $347.5 million (€316.2 million) in milestones.
4D landed the deal on the potential of its MicroRx technology. The platform enables 4D to identify strains that have significant effects on humans and target disease pathways that may be modulated by these host-bacteria interactions. 4D is mainly using the approach to go after solid tumors and gastrointestinal diseases, but Merck is interested in a different application of the technology.
“By applying 4D’s MicroRx technology we hope to gain meaningful insights into the role for the host microbiome in modulating the immune response and ultimately protection conferred by vaccines,” Merck’s Daria Hazuda said in a statement.
To gain those insights, Merck is paying an upfront cash payment of undisclosed size for each of the three indications covered by the deal. 4D has also gained the right to make Merck buy $5 million of its stock during the first year of the collaboration, plus a shot at reeling in up to $347.5 million in milestones. The agreement features tiered royalties, too.
Merck will do most of the heavy lifting on any programs that advance out of the lab. 4D will use its MicroRx platform to get the programs—which are at the discovery stage—going, but Merck will take over for development, manufacturing and commercialization.
The agreement adds another facet to the relationship between 4D and Merck. Last year, 4D joined the list of companies to gain access to Merck’s Keytruda for a clinical development program, setting it up to test its live biotherapeutic MRx0518 in combination with the checkpoint inhibitor in patients with solid tumors.
Shares in 4D rose more than 20% after news of the latest Merck deal emerged. The increase added to gains in recent weeks, over which time 4D’s share price has shot up from below £70 to above £120.
https://www.fiercebiotech.com/biotech/merck-taps-4d-pharma-for-bacterial-vaccine-r-d-project

SmileDirectClub hits new lows

Recent IPO SmileDirectClub (SDC -10.6%) has completed a round trip from a brief rally at the end of last week. Shares are now down almost 50% from its $23 offering price on concerns with corporate governance (appearance of self-dealing by Chairman & CEO David Katzman) and the safety and legitimacy of its teledentistry platform.
Analysts at IPO underwriters have been vocal cheerleaders with a bolus of recent Buy ratings in an effort to stem the selling, a futile effort thus far.
https://seekingalpha.com/news/3504535-smiledirectclub-hits-new-lows-11-percent

California bans pharma’s infamous ‘pay-for-delay’ deals

When generic challengers come for a branded med’s patent, drugmakers have in the past chosen to pony up and stall their rivals with an anticompetitive pact better known as “pay for delay.” In an effort to keep drug prices down, California is looking to end the practice.
California Gov. Gavin Newsom signed a new bill Tuesday that will make California the first state to ban pay-for-delay deals in pharma.
The bill, AB 824, will make it unlawful for companies to exchange anything of value in return for a halt to patent challenges from generic drugmakers. That new measure could open the door to a range of civil suits against companies seeking to keep generic competitors off the market.
“California will use our market power and our moral power to take on big drug companies and prevent them from keeping affordable generic drugs out of the hands of people who need them,” Newsom said in a statement.

California’s ban is the most recent regulatory assault on pay-for-delay deals after the U.S. Supreme Court in 2013 freed the Federal Trade Commission (FTC) to challenge brand-name drugmakers’ patent settlements with generics companies. In that 5-3 vote, the court reversed a circuit court’s ruling that shielded the companies from most lawsuits challenging their patent deals.
Soon after that ruling, European regulators rolled up their shirtsleeves in going after pay for delays. In July 2014, the EU fined six companies, including Teva, Mylan and Servier, more than a half-billion dollars for individual pay-for-deal infractions.
With regulators cracking the whip, the FTC reported in 2016 that pay-for-delay deals began to decline in 2014 after a multi-year explosion of such pacts between 2005 and 2012. In 2014, the FTC reported 21 suspected settlements compared to 40 in 2012 and 29 in 2013.
Despite the dip, pay for delays do still happen and often ensnare large-cap pharmas.
In August, a federal judge approved a $65.8 million settlement between Teva’s Cephalon and five plaintiffs on charges the drugmaker incentivized challengers to keep narcolepsy drug Provigil imitators off the market to protect the now-generic drug’s sales.
The civil suit comes four years after Teva agreed to pay out $1.2 billion to settle a Federal Trade Commission probe into similar charges that the Israeli drugmaker promised competitors Mylan and Sun Pharmaceuticals payment for active ingredients and intellectual property—deals that made “no economic sense” for Cephalon beyond stopping competition.

In April, the FTC knocked Impax, concluding the company entered a pay-for-delay deal with Endo to put off copies of opioid painkiller Opana ER.
The agency said Endo controlled the market for the pain drug and gave Impax a “large and unjustified payment” to deter generic competition. Under the deal, Endo agreed to pay Impax more if Opana’s market shrank before the generic launch, the FTC said.
Endo also agreed to hold off on its authorized generic during Impax’s 180-day period of generic exclusivity. The FTC said Impax couldn’t reasonably justify the cash payment that changed hands.
The FTC previously alleged Endo paid Impax $112 million in 2010 to delay its generic until January 2013. In 2017, amid worries about Opana ER’s potential for abuse, Endo pulled the drug off the market at the FDA’s request.
https://www.fiercepharma.com/pharma/california-governnor-inks-bill-banning-pay-for-delay-deals-pharma